311 related articles for article (PubMed ID: 12570013)
21. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback.
Monjanel-Mouterde S; Ciccolini J; Bagarry D; Zonta-David M; Duffaud F; Favre R; Durand A
J Clin Pharm Ther; 2003 Apr; 28(2):109-16. PubMed ID: 12713607
[TBL] [Abstract][Full Text] [Related]
24. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
25. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.
Johansen MJ; Madden T; Mehra RC; Wood JG; Rondon G; Browne V; Newman RA; Champlin RE
J Clin Oncol; 1997 Apr; 15(4):1481-91. PubMed ID: 9193344
[TBL] [Abstract][Full Text] [Related]
26. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
Cardoso E; Csajka C; Schneider MP; Widmer N
Clin Pharmacokinet; 2018 Jan; 57(1):1-6. PubMed ID: 28634655
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring in cancer chemotherapy.
Bach DM; Straseski JA; Clarke W
Bioanalysis; 2010 May; 2(5):863-79. PubMed ID: 21083218
[TBL] [Abstract][Full Text] [Related]
28. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
29. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
30. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
Guillet P; Monjanel S; Nicoara A; Duffaud F; Lacarelle B; Bagarry-Liegey D; Durand A; Catalin J; Favre R
Cancer Chemother Pharmacol; 1997; 40(2):143-9. PubMed ID: 9182836
[TBL] [Abstract][Full Text] [Related]
31. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children.
Doz F; Urien S; Chatelut E; Michon J; Rubie H; Zucker JM; Canal P; Bastian G
Cancer Chemother Pharmacol; 1998; 42(3):250-4. PubMed ID: 9685062
[TBL] [Abstract][Full Text] [Related]
32. Schedule-dependent topoisomerase II-inhibiting drugs.
Joel SP; Slevin ML
Cancer Chemother Pharmacol; 1994; 34 Suppl():S84-8. PubMed ID: 8070033
[TBL] [Abstract][Full Text] [Related]
33. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.
Chatelut E; Pivot X; Otto J; Chevreau C; Thyss A; Renée N; Milano G; Canal P
Eur J Cancer; 2000 Jan; 36(2):264-9. PubMed ID: 10741287
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
35. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
[TBL] [Abstract][Full Text] [Related]
36. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
37. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.
Rubie H; Doz F; Vassal G; Chastagner P; Gentet JC; Urien S; Bastian G; Drouard-Troalen L; Barberi-Heyob M; Catalin J; Chatelut E;
Eur J Cancer; 2003 Jul; 39(10):1433-8. PubMed ID: 12826047
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetics and therapeutic drug monitoring of anticancer agents].
Marquet P; Rousseau A
Bull Cancer; 2008 Oct; 95(10):903-9. PubMed ID: 19004719
[TBL] [Abstract][Full Text] [Related]
39. A sequential Bayesian algorithm for dose individualisation of carboplatin.
Duffull SB; Begg EJ; Robinson BA; Deely JJ
Cancer Chemother Pharmacol; 1997; 39(4):317-26. PubMed ID: 9025772
[TBL] [Abstract][Full Text] [Related]
40. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach.
Hon YY; Evans WE
Clin Chem; 1998 Feb; 44(2):388-400. PubMed ID: 9474050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]